Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

Rhea-AI Summary

Mangoceuticals (NASDAQ: MGRX) launched MangoRx Direct and PeachesRx Direct on Nov 13, 2025 to provide telehealth access, clinical monitoring, and fulfillment for branded GLP-1 obesity drugs Zepbound (tirzepatide) via LillyDirect and Wegovy (semaglutide) via NovoCare. The company offers a medication-management membership at $99/month and states GLP-1 drugs are available at fixed cash-pay pricing starting $499/month with home delivery or local pharmacy pickup.

The release also notes a Novo Nordisk spokesperson saying Novo Nordisk has no agreement with Mangoceuticals, and references White House pricing initiatives targeting $245/month government prices and other program pricing changes in 2026.

Positive

• Membership pricing at $99/month for unlimited telehealth and coaching
• Branded GLP-1 access advertised with cash-pay pricing starting $499/month
• Telehealth platform includes virtual consults and ongoing clinical monitoring

Negative

• Novo Nordisk spokesperson stated no agreement exists with Mangoceuticals
• Advertised cash-pay pricing ($499/month) exceeds White House target pricing of $245/month

Insights

Strategic Healthcare Access Analyst

Mangoceuticals announces direct-access GLP-1 programs but partner confirmation is mixed; operational details and pricing clarity will determine real impact.

Mangoceuticals says it launched MangoRx Direct and PeachesRx Direct to provide branded Zepbound (tirzepatide) and Wegovy (semaglutide) via third-party pharmacy channels while offering a $99/month membership and claiming medication pricing from $499 per month down to program-linked prices cited from government negotiations. The stated model bundles telehealth visits, personalized plans, and fulfillment through LillyDirect® and NovoCare or a patient’s local pharmacy.

Material dependencies and risks are explicit in the text: the announced access relies on third-party pharmacy programs and on broader pricing actions referenced from a government-level initiative, including quoted targets of $245/month, a $50 Medicare copay effective mid-2026, and oral starters at $149/month. A Novo Nordisk spokesperson is quoted denying awareness or an agreement, which creates immediate uncertainty about the scope of branded product availability via the named manufacturer channel.

Watch for concrete confirmations of pharmacy agreements and fulfillment mechanics, published pricing and enrollment figures, and any clarification by Eli Lilly or Novo Nordisk within the next few weeks to months; regulatory or manufacturer statements by mid-2026 tied to the government pricing actions also matter. Given the press release facts, this is informative but ambiguous on execution and partner consent, so the near-term impact is assessed as neutral.

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and Wegovy® (semaglutide) from Novo Nordisk.

These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly’s LillyDirect® Self Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy. Through MangoRx and PeachesRx’s secure telehealth platform, customers will receive virtual consultations with board-certified providers, personalized obesity and weight management treatment plans, ongoing clinical monitoring and support, and to the extent eligible, fulfillment of these U.S. Food and Drug Administration (FDA)-approved GLP-1 medications via partner pharmacies or through their neighborhood pharmacies of choice.

Update (12:00 ET) A Novo Nordisk spokesperson stated: "Novo Nordisk was not made aware of the announcement issued this morning by Mangoceuticals. We do not have any agreement or partnership with this company."

“We’re working to make world-class weight-loss treatment simple and sustainable,” said Jacob Cohen, CEO of Mangoceuticals. “For just $99/month, our medication management membership, includes unlimited telehealth visits, personalized progress tracking, and lifestyle coaching. GLP-1 medications are provided separately at fixed cash-pay pricing through LillyDirect® and NovoCare programs, starting as low as $499 per month with free home delivery. Patients also have the flexibility to pick up prescriptions at their neighborhood pharmacies of choice upon request. No insurance is required, making the programs ideal for self-pay, uninsured, underinsured and high-deductible patients.”

This launch supports and comes in conjunction with the White House’s recent historic announcement, securing landmark deals with Eli Lilly and Novo Nordisk to reduce government pricing of certain GLP-1 medications to $245/month, offer $50 copays for Medicare patients with obesity (effective mid-2026), launch oral GLP-1 starters as low as $149/month via TrumpRx (to the extent approved by the FDA), and work to drive average costs for Wegovy and Zepbound to $350 or less per month.

With obesity affecting 42% of U.S. adults and costing the healthcare system over $210 billion annually, Mangoceuticals believes it is positioned to serve millions seeking safe, effective, and affordable solutions.

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, relating to, among other things: statements about the benefits of our partnership with Eli Lilly and Novo Nordisk, the ability of our trials to demonstrate safety and efficacy of our product candidates, and other positive results; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; the Company’s reliance on third parties to conduct its clinical trials; unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability claims; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; including the risk that final results could differ from interim data released; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; the progress of our clinical trials; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care and other of our products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment; potential lawsuits, claims and actions; the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management’s resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; our ability to meet the continued listing requirements of Nasdaq; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“FDA”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“FFDCA Act”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; claims, lawsuits and litigation relating to our intellectual property, including allegations that our intellectual property infringes on the intellectual property of others, costs related to any such claims or lawsuits and resources required to expend in connection therewith; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel), tariffs, trade wars, and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

FOR INVESTOR RELATIONS

Mangoceuticals Investor Relations

Email: investors@mangorx.com

FAQ

What did Mangoceuticals announce on Nov 13, 2025 about Zepbound and Wegovy (MGRX)?

Mangoceuticals launched MangoRx Direct and PeachesRx Direct to offer telehealth access and fulfillment for Zepbound via LillyDirect and Wegovy via NovoCare.

How much does Mangoceuticals' medication management membership cost (MGRX)?

The company states the membership costs $99/month and includes unlimited telehealth visits and lifestyle coaching.

What cash-pay prices did Mangoceuticals cite for GLP-1 medications (MGRX)?

Mangoceuticals said GLP-1 medications start at $499/month with free home delivery, paid separately from the membership.

Does Novo Nordisk confirm a partnership with Mangoceuticals (MGRX)?

A Novo Nordisk spokesperson said Novo Nordisk was not made aware of the announcement and has no agreement with Mangoceuticals.

How does Mangoceuticals' pricing compare with White House GLP-1 initiatives cited on Nov 13, 2025 (MGRX)?

The release references White House targets lowering some government prices to $245/month, which is below the company’s cited $499/month starting cash-pay price.

Are insurance requirements needed to access Mangoceuticals' GLP-1 programs (MGRX)?

No insurance is required; the programs are described as suited for self-pay, uninsured, underinsured, and high-deductible patients.